Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor.

The company has filed an Abbreviated New Drug Application (ANDA) for NRX-100, preservative-free IV ketamine and has initiated filing of an NDA for NRX-100 in people with suicidal depression.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is traded on the Nasdaq Global Select Exchange.

Stock Data

Volume
Market Cap
Currency in USD.

Corporate Presentation

Click here to view our corporate presentation or on the image below
Corporate Presentation

Detailed Quote

Minimum 15 minutes delayed. Source: LSEG

Recent News

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
March 30, 2026
Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via

For more news and articles, visit our news page.

IP Portfolio
View Our Pipeline
Contact NRx Pharmaceuticals